Table 1 Characteristics of patients with JIA and healthy children at baseline and 2-year follow-up*
Baseline | 2 year follow-up | |||
|---|---|---|---|---|
JIA patients(n = 90) | Controls(n = 90) | JIA patients(n = 90) | Controls(n = 90) | |
Characteristics | ||||
Female, n (%) | 56 (62%) | 56 (62%) | 56 (62%) | 56 (62%) |
Age, mean (SD) years | 10.1 (3.2) | 10.1 (3.2) | 12.1 (3.2) | 12.2 (3.2) |
Disease-onset type, n (%) | ||||
Oligoarthritis, persistent | 48 (53%) | - | 48 (53%) | - |
Oligoarthritis, extended | 11 (12%) | - | 11 (12%) | - |
Polyarthritis, RF negative | 28 (31%) | - | 28 (31%) | - |
Polyarthritis, RF positive | 3 (3%) | - | 3 (3%) | - |
Disease duration, mean (SD) months | 19.4 (12.3) | - | 44.3 (14.2) | - |
No. of joints with active disease, mean (SD) † | 2.2 (3.5) | - | 1.3 (4.2) | - |
No. of joints with restricted mobility, mean (SD) † | 1.7 (2.6) | - | 1.2 (2.2) | - |
Radiographic score, mean (SD) ‡ | 1.7 (0.6) | - | 1.8 (0.6) | - |
Radiographic erosions, n (%) § | 3 (3%) | - | 5 (6%) | - |
Radiographic progression, n (%)¶ | - | - | 9 (10%) | - |
Total body BMC Z-score < -1, n (%) | 10 (11%) | 9 (10%) | 20 (22%) | 12 (13%) |
Disease-modifying antirheumatic drugs, current use, n (%) | 48 (53%) | - | 37 (41%) # | - |
Non-steroidal anti-inflammatory drugs, current use, n (%) | 68 (76%) | 43 (48%) | ||
Oral corticosteroids ** | ||||
Current use, n (%) | 17 (19%) | - | 8 (9%) | - |
Dosage, mean (SD) mg/day | 11.2 (7.1) | - | 6.7 (5.9) | - |
Ever used, n (%) | 27 (30%) | - | 31 (34%) | - |
Cumulative dose, mean (SD) mg | 1234 (1328) | - | 1919 (2062) | - |
Cumulative dose, mean (SD) mg/kg of body weight | 38 (42) | - | 52 (65) | - |